行情

EGRX

EGRX

Eagle制药
NASDAQ

实时行情|Nasdaq Last Sale

49.03
-0.25
-0.51%
盘后: 49.03 0 0.00% 16:00 09/20 EDT
开盘
48.47
昨收
49.28
最高
49.50
最低
48.44
成交量
9.40万
成交额
--
52周最高
55.50
52周最低
36.48
市值
6.42亿
市盈率(TTM)
36.14
分时
5日
1月
3月
1年
5年
提醒:Eagle Pharmaceuticals 将于 2021 年 9 月 9 日举办 CAL02 投资者活动
WOODCLIFF LAKE, N.J., September 07, 2021--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature other gu...
Business Wire · 09/07 10:50
Eagle Pharmaceuticals 将出席 9 月的医疗保健会议
WOODCLIFF LAKE, N.J., September 01, 2021--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at two upcoming investor co...
Business Wire · 09/01 21:00
2021年9月1日公司新闻
Companies in the news are: NTES, SONN, EGRX, ZEV
Zacks · 09/01 13:41
The Daily Biotech Pulse:默克发布双倍积极消息,安斯泰来自愿暂停基因治疗研究,Ascendis 产品
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 11:32
BRIEF-Endo Comments On Non-Infringement Ruling In VASOSTRICT Patent Litigation
reuters.com · 08/31 18:13
在 Vasostrict 的法律挫折后,Endo 在 Piper Sandler 的评级下调
Piper Sandler has lowered its rating on Endo International (NASDAQ:ENDP) to neutral from overweight after a court ruling determined that Eagle Pharmaceuticals (NASDAQ:EGRX) with its marketing application for Vasopressin did
Seekingalpha · 08/31 18:12
Endo 对 VASOSTRICT® 专利诉讼中的非侵权裁决的评论
/PRNewswire/ -- Endo International plc ("Endo") (NASDAQ: ENDP) today commented on District Court for the District of non-infringement ruling in favor of Eagle Pharmaceuticals Inc. ("Eagle") in patent litigation regarding Eagle's abbreviated new drug appl...
PR Newswire - PRF · 08/31 18:09
周二涨幅居前的 5 只股票:维珍银河、数字涡轮机
Virgin Galactic, Digital Turbine, AC Immune SA, Spok Holdings and Eagle Pharmaceuticals are five top stock gainers for Tuesday.
TheStreet.com · 08/31 16:33
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解EGRX最新的财务预测,通过EGRX每股收益,每股净资产,每股现金流等数据分析Eagle制药近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测EGRX价格均价为48.50,最高价位51.00,最低价为46.00。
EPS
机构持股
总机构数: 241
机构持股: 1,566.29万
持股比例: 119.59%
总股本: 1,309.71万
类型机构数股数
增持
57
123.66万
建仓
11
32.24万
减持
52
62.73万
平仓
20
98.47万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.35%
制药与医学研究
-1.08%
高管信息
Non-Executive Chairman/Independent Director
Michael Graves
President/Chief Operating Officer
David Pernock
Chief Executive Officer/Director
Scott Tarriff
Chief Financial Officer
Brian Cahill
Executive Vice President
Judith Ng-Cashin
Independent Director
Luciana Borio
Independent Director
Richard Edlin
Independent Director
Robert Glenning
Independent Director
Steven Ratoff
Independent Director
Jennifer Simpson
暂无数据
EGRX 简况
Eagle Pharmaceuticals, Inc.是一家专业制药公司。该公司致力于开发和销售重症监护和肿瘤学领域的注射产品。该公司的产品组合包括EP-1101(阿加曲班)、Ryanodex(丹曲林钠)、多西他赛注射剂、非酒精制剂(非酒精多西他赛注射)、双氯芬酸 - 米索前列醇、EP-3101(盐酸苯达莫司汀注射液,即用型稀释液(RTD)浓缩液)和EP-3102(快速输注的苯达莫司汀RTD)(EP-3102 Bendeka)。它在开发的高级阶段的四个候选产品正在由美国食品和药物管理局(FDA)审查进行批准,包括EP-6101康吉奥即用型(RTU)比伐卢定、用于劳力性热射病的EP-4104(丹曲林钠)(EP-4104)和EP-5101(培美曲塞)(EP-5101)。其近期候选产品,Kangio是一种用于经皮腔内血管成形术的比伐卢定液体静脉注射产品。

微牛提供Eagle Pharmaceuticals Inc(NASDAQ-EGRX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的EGRX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易EGRX股票基本功能。